Deutsch
Englisch
AXADIA:
A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment
PATIENTS
Recruitment was stopped on the 31th of May 2022.
97 patients randomised
22 sites open
108
Planned number of patients
PARTICIPATING COUNTRIES
Germany
PUBLICATIONS
Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff H, Gerss J, Haeusler KG, Hewing B, Hoyer J, Juergensmeyer S, Klingenheben T, Knapp G, Rump LC, Schmidt-Guertler H, Wanner C, Kirchhof P, Goerlich D. 2022. A randomized controlled trial comparing apixaban to the vitamin Kantagonist phenprocoumon in patients on chronic hemodialysis – the AXADIA – AFNET 8 study. Circulation 06.11.2022. doi: 10.1161/CIRCULATIONAHA.122.062779
Reinecke H, Jürgensmeyer S, Engelbertz C, et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018 Sep 10;8:e022690. doi: 10.1136/bmjopen-2018-022690
Co-ordinating Investigator Cardiology/ Head of the Trial:
Holger Reinecke, MD, University Hospital, Münster, Germany
Co-ordinating Investigator Nephrology/ Chief Investigator:
Christoph Wanner, MD, University Hospital Würzburg, Germany
Overall Responsibility
Legal Sponsor according to the EU directive 2001/ 20/ EC:
Atrial Fibrillation NETwork (AFNET), Münster, Germany